Clinical Pathology Department, Damietta Cancer Institute, Damietta, Egypt.
Chemistry Department, Faculty of Science, Menoufia University, Shebin el-kom, Egypt.
Asian Pac J Cancer Prev. 2023 May 1;24(5):1725-1730. doi: 10.31557/APJCP.2023.24.5.1725.
BACKGROUND/AIMS: Tumor metastasis involves the dissemination of malignant cells into the basement membrane and vascular system contributes to the circulating pool of these markers. In this context our aim has been focused on development of a non-invasive score based on degradation of glycosaminoglycans in the extracellular matrix for assessment of metastasis in patients with breast cancer. Circulating tumor cells (CTCs) represent a unique liquid biopsy carrying comprehensive biological information of the primary tumor. Herein, we sought to develop a novel score based on the combination of the most significant CTCs biomarkers with and routine laboratory tests for accurate detection of Metastases in patients with breast cancer.
MATERIAL & METHODS: Cytokeratin 18 (CK18), Cytokeratin 19 (CK19) and CA15.3 were assayed in metastatic breast cancer patients (88), non-metastatic breast cancer patients (129) and healthy control (32). Areas under receiving operating curve (AUCs) were calculated and used for construction on novel score. A novel score named CTC-MBS = CA15.3 (U/L) × 0.08 + CK 18 % × 2.9 + CK19 × 3.1. CTC-MBS score produces AUC of 1 for differentiate patients with metastatic breast cancer from those with non-metastatic breast cancer with sensitivity and specificity of a cut-off 0 (i.e., less than 0 the case is considered metastatic, whereas above 0 it is considered non-metastatic.
CTC-MBS score is a novel, non-invasive and simple can applied to discriminate patients with metastatic breast cancer and could replace CA15.3 during screening and follow-up of breast cancer patients.
背景/目的：肿瘤转移涉及恶性细胞向基底膜的扩散，血管系统有助于这些标志物的循环池。在这种情况下，我们的目标一直集中在开发一种非侵入性评分上，该评分基于细胞外基质中糖胺聚糖的降解，用于评估乳腺癌患者的转移。循环肿瘤细胞（CTC）代表一种独特的液体活检，携带原发性肿瘤的综合生物学信息。在此，我们试图开发一种基于最显著的 CTC 标志物与常规实验室测试相结合的新型评分，以准确检测乳腺癌患者的转移。
在转移性乳腺癌患者（88 例）、非转移性乳腺癌患者（129 例）和健康对照组（32 例）中检测细胞角蛋白 18（CK18）、细胞角蛋白 19（CK19）和 CA15.3。计算接收者操作曲线（AUC）的面积，并用于构建新型评分。一种名为 CTC-MBS 的新型评分命名为 CA15.3（U/L）×0.08+CK18%×2.9+CK19×3.1。CTC-MBS 评分产生 1 的 AUC 用于区分转移性乳腺癌患者与非转移性乳腺癌患者，其灵敏度和特异性为截断值 0（即，小于 0 的病例被认为是转移性的，而大于 0 的病例被认为是非转移性的。
CTC-MBS 评分是一种新型的、非侵入性的、简单的评分，可以应用于区分转移性乳腺癌患者，并且可以在乳腺癌患者的筛查和随访中替代 CA15.3。
